Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.
Earnings and Valuation
This table compares Bolt Biotherapeutics and Sutro Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bolt Biotherapeutics | $7.70 million | 0.98 | -$33.38 million | ($16.44) | -0.24 |
| Sutro Biopharma | $102.48 million | 3.32 | -$191.09 million | ($11.97) | -1.72 |
Profitability
This table compares Bolt Biotherapeutics and Sutro Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
| Sutro Biopharma | -395.25% | N/A | -88.12% |
Volatility and Risk
Bolt Biotherapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Bolt Biotherapeutics and Sutro Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
Bolt Biotherapeutics presently has a consensus price target of $14.50, indicating a potential upside of 272.75%. Sutro Biopharma has a consensus price target of $47.30, indicating a potential upside of 130.28%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Sutro Biopharma.
Insider & Institutional Ownership
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Sutro Biopharma beats Bolt Biotherapeutics on 10 of the 15 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
